Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM TSE:IAM NASDAQ:SBC NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.49-2.4%$4.47$2.33▼$36.00$6.75M0.9864,448 shs27,165 shsIAMIntegrated Asset ManagementC$0.00C$1.52▼C$2.92C$75.96MN/A30,209 shs8,780 shsSBCSBC Medical Group$4.48-0.9%$4.53$2.62▼$12.50$465.39M1.2765,758 shs51,097 shsXLYConsumer Discretionary Select Sector SPDR Fund$242.18+0.6%$227.23$173.10▼$242.77$24.31B1.184.75 million shs4.33 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-2.31%-1.93%-4.15%-75.62%-91.44%IAMIntegrated Asset Management0.00%0.00%0.00%0.00%0.00%SBCSBC Medical Group+0.89%-9.42%+1.35%-0.22%+451,999,900.00%XLYConsumer Discretionary Select Sector SPDR Fund+0.87%+1.98%+5.09%+14.44%+25.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.49-2.4%$4.47$2.33▼$36.00$6.75M0.9864,448 shs27,165 shsIAMIntegrated Asset ManagementC$0.00C$1.52▼C$2.92C$75.96MN/A30,209 shs8,780 shsSBCSBC Medical Group$4.48-0.9%$4.53$2.62▼$12.50$465.39M1.2765,758 shs51,097 shsXLYConsumer Discretionary Select Sector SPDR Fund$242.18+0.6%$227.23$173.10▼$242.77$24.31B1.184.75 million shs4.33 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-2.31%-1.93%-4.15%-75.62%-91.44%IAMIntegrated Asset Management0.00%0.00%0.00%0.00%0.00%SBCSBC Medical Group+0.89%-9.42%+1.35%-0.22%+451,999,900.00%XLYConsumer Discretionary Select Sector SPDR Fund+0.87%+1.98%+5.09%+14.44%+25.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.50Strong Buy$275.0010,944.18% UpsideIAMIntegrated Asset Management 0.00N/AN/AN/ASBCSBC Medical Group 0.00N/AN/AN/AXLYConsumer Discretionary Select Sector SPDR Fund 2.66Moderate Buy$242.18N/ACurrent Analyst Ratings BreakdownLatest IAM, AIM, XLY, and SBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AIMAIM ImmunoTechMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K55.75N/AN/A$0.20 per share12.45IAMIntegrated Asset ManagementC$18.31M0.00N/A4.43C$0.67 per share0.00SBCSBC Medical Group$188.19M2.47$0.61 per share7.39$1.90 per share2.36XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/AIAMIntegrated Asset ManagementN/AC$0.1124.91N/AN/AN/AN/AN/AN/ASBCSBC Medical Group$46.61M$0.3214.000.80N/A17.71%20.76%15.56%11/12/2025 (Estimated)XLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ALatest IAM, AIM, XLY, and SBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SBCSBC Medical Group$0.14$0.02-$0.12$0.02$44.71 million$43.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AIAMIntegrated Asset ManagementC$0.114.38%N/A100.00%N/ASBCSBC Medical GroupN/AN/AN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.75%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75IAMIntegrated Asset ManagementN/A4.854.81SBCSBC Medical Group0.033.983.95XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%IAMIntegrated Asset ManagementN/ASBCSBC Medical Group60.82%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%IAMIntegrated Asset ManagementN/ASBCSBC Medical Group89.47%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableIAMIntegrated Asset Management5627.72 millionN/ANot OptionableSBCSBC Medical GroupN/A103.88 million10.94 millionN/AXLYConsumer Discretionary Select Sector SPDR Fund147,000100.40 millionN/ANot OptionableIAM, AIM, XLY, and SBC HeadlinesRecent News About These CompaniesStock Market News for Sep 11, 2025September 11, 2025 | finance.yahoo.comWhat August Labor Data Means for the S&P 500 in September (XLY)...September 8, 2025 | marketbeat.comReturn of the ETFs: 3 Names That Could Keep Outperforming (XLY)...September 4, 2025 | marketbeat.comTrade's Biggest Threat Isn't Tariffs—It's UncertaintySeptember 3, 2025 | msn.comWhat to Expect From the Q3 Reporting Season (XLY)...September 3, 2025 | marketbeat.comRoyal Caribbean, Deckers, MGM Shine As Consumer Stocks Extend Weekly Gains After Powell's Rate-Cut TeaseAugust 25, 2025 | msn.comXLY: Don't Expect Consumer Spending To Notably Recover Until 2026August 21, 2025 | seekingalpha.comConsumer Strength Signal Flashing Short-Term Caution SignAugust 20, 2025 | schaeffersresearch.comAre Cyclical ETFs Worth the Boom and Bust?August 18, 2025 | finance.yahoo.comLululemon, Wendy’s, Peloton Get Some Institutional Love As Hedge Funds Shuffle Consumer Stocks DeckAugust 15, 2025 | msn.com5 ETFs to Benefit if Fed Cuts Rate in SeptemberAugust 11, 2025 | zacks.comWhat Tariffs Mean for Your Sector ExposureAugust 8, 2025 | msn.comShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?August 6, 2025 | zacks.comTrump Tariff Blows Didn’t Stop These 3 Stocks From Defying Last Week’s Consumer SlumpAugust 4, 2025 | msn.comLooking for Exposure to Amazon Stock (AMZN) Post Q2 Dip? Try These Two ETFsAugust 2, 2025 | msn.comStrong Start to Q2 Earnings Season: 4 Sector ETFs to PlayJuly 30, 2025 | zacks.com4 Sector ETFs to Play on Improving Earnings TrendsJuly 28, 2025 | zacks.comEarnings Scoreboard: 12 of 17 consumer cyclical stocks beat estimates last weekJuly 27, 2025 | msn.comConsumer Durables: Overview, What They Are, ExampleJuly 25, 2025 | fool.comETFs to Consider as Consumer Sentiment Improves in JulyJuly 21, 2025 | zacks.comWeekly Economic Snapshot: Consumer Spending Rebounds Despite Rising InflationJuly 21, 2025 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIs It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025Why DocuSign Could Be a SaaS Value Play After Q2 EarningsBy Chris Markoch | September 5, 2025IAM, AIM, XLY, and SBC Company DescriptionsAIM ImmunoTech NYSE:AIM$2.49 -0.06 (-2.35%) Closing price 03:58 PM EasternExtended Trading$2.52 +0.02 (+1.00%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Integrated Asset Management TSE:IAMIntegrated Asset Management Corp. operates as an alternative asset investment management company. The company provides investors with private equity, private corporate debt, managed futures, hedge funds, real estate investment management, property management and leasing, and merchant banking. It offers alternative asset class management to institutional, pension, and private clients. Integrated Asset Management Corp. was founded in 1998 and is headquartered in Toronto, Canada.SBC Medical Group NASDAQ:SBC$4.48 -0.04 (-0.88%) Closing price 04:00 PM EasternExtended Trading$4.49 +0.01 (+0.22%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$242.18 +1.48 (+0.61%) Closing price 04:10 PM EasternExtended Trading$241.89 -0.29 (-0.12%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
